| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 144 |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients |
| 05 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 23 Oct 2026 |
Form 4: Cobo Marc, Principal Accounting Officer
Gave up 203 shares to cover exercise price or tax ($544) |
| 05 Oct 2026 |
Form 4: Cobo Marc, Principal Accounting Officer
Gave up 126 shares to cover exercise price or tax ($496) |
| 05 Oct 2026 |
Form 4: Elmelech Idan, COO & Principal Financial Ofcr
Gave up 343 shares to cover exercise price or tax ($1.35K) |
| 05 Oct 2026 |
Form 4: Beltran Pedro, Director
Gave up 1,047 shares to cover exercise price or tax ($4.13K) |
| 05 Oct 2026 |
Form 4: Ben Yong, Chief Med & Dev Officer
Gave up 1,047 shares to cover exercise price or tax ($4.13K) |
| 14 Sep 2026 |
Form 4: Cobo Marc, Principal Accounting Officer
Received 9,038 shares as a grant or award · Gave up 203 shares to cover exercise price or tax ($1.12K) · Granted 43,700 Stock Option (Right to Buy) |
| 10 Sep 2026 | EFFECT |
| 08 Sep 2026 | EFFECT |
| 08 Sep 2026 |
8-K: Other Events
Corporate Update September 2026 BBOT Next-Generation RAS-Pathway Therapeutics |
| 01 Sep 2026 | S-3 |
| 01 Sep 2026 | POS AM |
| 12 Aug 2026 | 424B3 |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Continued to advance monotherapy and combination cohorts for all clinical programs |
| 06 Jul 2026 |
Form 4: Cobo Marc, Principal Accounting Officer
Gave up 125 shares to cover exercise price or tax ($975) |
Loading...